Sino Biological Completes Acquisition of SignalChem Biotech, Strengthening Global Presence and Expanding Product Portfolio

Sino Biological, Inc. (“Sino Biological” or the “Company”), a biotechnology company listed on Shenzhen stock exchange subsidiary ChiNext, specializing in biological research reagents and related technical contract research services, has successfully completed the acquisition of the Vancouver-based company. Canadian biotechnology company SignalChem Biotech Inc. (“SCB” or “SignalChem”). Sino Biological has acquired 100% of SCB shares in a deal valued at $48 million USD, including all assets, assumed debt and net of cash deposits.

SignalChem Biotech Inc. is known for its specialized bioactive enzymes, including kinases, proteases, phosphatases, ubiquitin and epigenetic enzymes. Over the past two decades, SCB has established proprietary manufacturing and quality control platforms, establishing industry standards for the development and production of high-quality bioactive enzyme proteins to support scientists from basic research to drug discovery and development. Now operating as a wholly owned subsidiary of Sino Biological, SCB will bring exclusive expertise in enzyme manufacturing to the company’s existing technology platforms.

The strategic synergy between Sino Biological and SignalChem enables the offering of a broader range of products and research services, supporting the broader life sciences community and facilitating the discovery and development of new treatments, vaccines and diagnostic platforms.

SignalChem is at the forefront of the development and production of enzyme bioreagents, as well as enzyme-based compound screening technologies. The acquisition of SCB further strengthens Sino Biological’s robust presence in the field of bioactive recombinant proteins and related contract research services.

Dr. Jie Zhang, president and general manager of Sino Biological

“We are excited to join forces with Sino Biological and begin this new chapter of growth and collaboration,” said Mr. Jun Yan, co-founder, president and CEO of SignalChem Biotech. “Together, we have a unique opportunity to leverage our complementary strengths and resources to accelerate innovation and better serve the scientific community. We look forward to combining our expertise to develop new solutions that address the complex challenges facing researchers around the world.”

Sino Biological remains committed to maintaining high standards of quality, reliability and customer satisfaction throughout the integration process. Customers can expect continued access to the same high-quality products and services they rely on, backed by the combined expertise and resources of Sino Biological and SignalChem Biotech.